Targeting signaling pathways in heart failure by gene transfer

Current Atherosclerosis Reports

Volumn 5, Issue 3, 2003, Pages 178-185

  MacNeill, Briain D ^a   Hayase, Motoya ^a   Hajjar, Roger J ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE TRIPHOSPHATASE (CALCIUM); CARIPORIDE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; NEUROHORMONE; PHOSPHOLAMBAN; POTASSIUM CHANNEL HERG;

APOPTOSIS; CONGESTIVE HEART FAILURE; DISEASE COURSE; GENE TARGETING; GENE THERAPY; GENE TRANSFER; GENE VECTOR; GENETIC MANIPULATION; HORMONAL REGULATION; ION TRANSPORT; NONHUMAN; REVIEW; SIGNAL TRANSDUCTION; GENETICS; HUMAN;

GENE TARGETING; GENE TRANSFER TECHNIQUES; HEART FAILURE, CONGESTIVE; HUMANS; SIGNAL TRANSDUCTION;

EID: 0038258990     PISSN: 15233804     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11883-003-0021-2     Document Type: Review

References (84)

1. Barrans JD, Allen PD, Stamatiou D, et al.: Global gene expression profiling of end-stage dilated cardiomyopathy using a human cardiovascular-based cDNA microarray. Am J Pathol 2002, 160:2035-2043.
2. Lopaschuk GD, Collins-Nakai RL, Itoi T: Developmental changes in energy substrate use by the heart. Cardiovasc Res 1992, 26(12):1172-1180.
3. Parker TG, Packer SE, Schneider MD: Peptide growth factors can provoke "fetal" contractile protein gene expression in rat cardiac myocytes. J Clin Invest 1990, 85:507-514.
4. Razeghi P, Young ME, Alcorn JL, et al.: Metabolic gene expression in fetal and failing human heart. Circulation 2001, 104:2923-2931.
5. Santalucia T, Camps M, Castello A, et al.: Developmental regulation of GLUT-1 (erythroid/Hep G2) and GLUT-4 (muscle/fat) glucose transporter expression in rat heart, skeletal muscle, and brown adipose tissue. Endocrinology 1992, 130:837-846.
6. Feinendegen LE, Henrich MM, Kuikka JT, et al.: Myocardial lipid turnover in dilated cardiomyopathy: a dual in vivo tracer approach. J Nucl Cardiol 1995, 2:42-52.
7. Kelly DP, Strauss AW: Inherited cardiomyopathies. N Engl J Med 1994, 330:913-919.
8. Jarreta D, Orus J, Barrientos A, et al.: Mitochondrial function in heart muscle from patients with idiopathic dilated cardiomyopathy. Cardiovasc Res 2000, 45:860-865.
9. Suomalainen A, Paetau A, Leinonen H, et al.: Inherited idiopathic dilated cardiomyopathy with multiple deletions of mitochondrial DNA. Lancet 1992, 340:1319-1320.
10. Du XJ, Autelitano DJ, Dilley RJ, et al.: β(2)-adrenergic receptor overexpression exacerbates development of heart failure after aortic stenosis. Circulation 2000, 101:71-77.
11. Stanley WC, Chandler MP: Energy metabolism in the normal and failing heart: potential for therapeutic interventions. Heart Fail Rev 2002, 7:115-130.
12. Barry WH, Bridge JH: Intracellular calcium homeostasis in cardiac myocytes. Circulation 1993, 87:1806-1815.
13. Koss KL, Kranias EG: Phospholamban: a prominent regulator of myocardial contractility. Circ Res 1996, 79:1059-1063.
14. Gwathmey JK, Bentivegna LA, Ransil BJ, et al.: Relationship of abnormal intracellular calcium mobilisation to myocyte hypertrophy in human ventricular myocardium. Cardiovasc Res 1993, 27:199-203.
15. Gwathmey JK, Morgan JP: Sarcoplasmic reticulum calcium mobilization in right ventricular pressure-overload hypertrophy in the ferret: relationships to diastolic dysfunction and a negative treppe. Pflugers Arch 1993, 422:599-608.
16. Mercadier JJ, Lompre AM, Duc P, et al.: Altered sarcoplasmic reticulum Ca2(+)-ATPase gene expression in the human ventricle during end-stage heart failure. J Clin Invest 1990, 85:305-309.
17. Hasenfuss C, Reinecke H, Studer R, et al.: Relation between myocardial function and expression of sarcoplasmic reticulum Ca(2+)-ATPase in failing and nonfailing human myocardium. Circ Res 1994, 75:434-442.
18. Beuckelmann DJ, Nabauer M, Erdmann E: Intracellular calcium handling in isolated ventricular myocytes from patients with terminal heart failure. Circulation 1992, 85:1046-1055.
19. Marx SO, Reiken S, Hisamatsu Y, et al.: PKA phosphorylation dissociates FKBP12.6 from the calcium release channel (ryanodine receptor): defective regulation in failing hearts. Cell 2000, 101:365-376.
20. Flesch M, Putz F, Schwinger RH, Bohm M: Functional relevance of an enhanced expression of the Na(+)-Ca2+ exchanger in the failing human heart. Ann N Y Acad Sci 1996, 779:539-542.
21. Flesch M, Schwinger RH, Schiffer F, et al.: Evidence for functional relevance of an enhanced expression of the Na(+)-Ca2+ exchanger in failing human myocardium. Circulation 1996, 94:992-1002.
22. Schillinger W, Janssen PM, Emami S, et al.: Impaired contractile performance of cultured rabbit ventricular myocytes after adenoviral gene transfer of Na(+)-Ca(2+) exchanger. Circ Res 2000, 87:581-587.
23. Schmidt AC, Zhai J, Carr AN, et al.: Structural and functional implications of the phospholamban hinge domain: impaired SR Ca2+ uptake as a primary cause of heart failure. Cardiovasc Res 2002, 56:248-259.
24. Packer M: The development of positive inotropic agents for chronic heart failure: how have we gone astray? J Am Coll Cardiol 1993, 22(4 suppl A):119A-126A.
25. Fowler MB, Laser JA, Hopkins GL, et al.: Assessment of the beta-adrenergic receptor pathway in the intact failing human heart: progressive receptor down-regulation and subsensitivity to agonist response. Circulation 1986, 74:1290-1302.
26. Lefkowitz RJ, Rockman HA, Koch WJ: Catecholamines, cardiac beta-adrenergic receptors, and heart failure. Circulation 2000, 101:1634-1637.
27. Hajjar RJ, Muller FU, Schmitz W, et al.: Molecular aspects of adrenergic signal transduction in cardiac failure. J Mol Med 1998, 76:747-755.
28. Rockman HA, Koch WJ, Lefkowitz RJ: Seven-transmem brane-spanning receptors and heart function. Nature 2002, 415:206-212.
29. Bristow MR: Why does the myocardium fail? Insights from basic science. Lancet 1998, 352(suppl 1):SI8-SI14.
30. Daaka Y, Luttrell LM, Lefkowitz RJ: Switching of the coupling of the beta2-adrenergic receptor to different G proteins by protein kinase A. Nature 1997, 390:88-91.
31. Zhu WZ, Zheng M, Koch WJ, et al.: Dual modulation of cell survival and cell death by beta(2)-adrenergic signaling in adult mouse cardiac myocytes. Proc Natl Acad Sci U S A 2001, 98:1607-1612.
32. Engelhardt S, Hein L, Wiesmann F, Lohse MJ: Progressive hypertrophy and heart failure in beta1-adrenergic receptor transgenic mice. Proc Natl Acad Sci U S A 1999, 96:7059-7064.
33. Liggett SB, Tepe NM, Lorenz JN, et al.: Early and delayed consequences of beta(2)-adrenergic receptor overexpression in mouse hearts: critical role for expression level. Circulation 2000, 101:1707-1714.
34. Wagoner LE, Craft LL, Singh B, et al.: Polymorphisms of the beta(2)-adrenergic receptor determine exercise capacity in patients with heart failure. Circ Res 2000, 86:834-840.
35. Liggett SB, Wagoner LE, Craft LL, et al.: The Ile 164 beta2-adrenergic receptor polymorphism adversely affects the outcome of congestive heart failure. J Clin Invest 1998, 102:1534-1539.
36. Hajjal RJ, Kang JX, Gwathmey JK, Rosenzweig A: Physiological effects of adenoviral gene transfer of sarcoplasmic reticulum calcium ATPase in isolated rat myocytes. Circulation 1997, 95:423-429.
37. Sumbilla C, Cavagna M, Zhong L, et al.: Comparison of SERCA1 and SERCA2a expressed in COS-1 cells and cardiac myocytes. Am J Physiol 1999, 277(6 Pt 2):H2381-H2391.
38. Hajjar RJ, Schmidt U, Kang JX, et al.: Adenoviral gene transfer of phospholamban in isolated rat cardiomyocytes. Rescue effects by concomitant gene transfer of sarcoplasmic reticulum Ca(2+)-ATPase. Circ Res 1997, 81:145-153.
39. del Monte F, Williams E, Lebeche D, et al.: Improvement in survival and cardiac metabolism after gene transfer of sarcoplasmic reticulum Ca(2+)-ATPase in a rat model of heart failure. Circulation 2001, 104:1424-1429.
40. Chossat N, Griscelli F, Jourdon P, et al.: Adenoviral SERCA1a gene transfer to adult rat ventricular myocytes induces physiological changes in calcium handling. Cardiovasc Res 2001, 49:288-297.
41. Miyamoto MI, del Monte F, Schmidt U, et al.: Adenoviral gene transfer of SERCA2a improves left-ventricular function in aortic-banded rats in transition to heart failure. Proc Natl Acad Sci U S A 2000, 97:793-798.
42. He H, Meyer M, Martin JL, et al.: Effects of mutant and antisense RNA of phospholamban on SR Ca(2+)- ATPase activity and cardiac myocyte contractility. Circulation 1999, 100:974-980.
43. Hoshijima M, Ikeda Y, Iwanaga Y, et al.: Chronic suppression of heart-failure progression by a pseudophosphorylated mutant of phospholamban via in vivo cardiac rAAV gene delivery. Nat Med 2002, 8:864-871.
44. Baartscheer A: Adenovirus gene transfer of SERCA in heart failure. A promising therapeutic approach? Cardiovasc Res 2001, 49:249-252.
45. Nagano M, Higaki J, Nakamura F, et al.: Role of cardiac angiotensin II in isoproterenol-induced left ventricular hypertrophy. Hypertension 1992, 19(6 Pt 2):708-712.
46. Golomb E, Abassi ZA, Coca G, et al.: Angiotensin II maintains, but does not mediate, isoproterenol-induced cardiac hypertrophy in rats. Am J Physiol 1994, 267(4 Pt 2):H1496-H1506.
47. Leenen FH, White R, Yuan B: Isoproterenol-induced cardiac hypertrophy: role of circulatory versus cardiac renin-angiotensin system. Am J Physiol Heart Circ Physiol 2001, 281:H2410-H2416.
48. Engelhardt S, Hein L, Keller U, et al.: Inhibition of Na(+)-H(+) exchange prevents hypertrophy, fibrosis, and heart failure in beta(1)-adrenergic receptor transgenic mice. Circ Res 2002, 90:814-819.
49. Nuss HB, Marban E, Johns DC: Overexpression of a human potassium channel suppresses cardiac hyperexcitability in rabbit ventricular myocytes. J Clin Invest 1999, 103:889-896.
50. Hajjar RJ, Schmidt U, Matsui T, et al.: Modulation of ventricular function through gene transfer in vivo. Proc Natl Acad Sci U S A 1998, 95:5251-5256.
51. Maurice JP, Hata JA, Shah AS, et al.: Enhancement of cardiac function after adenoviral-mediated in vivo intracoronary beta2-adrenergic receptor gene delivery. J Clin Invest 1999, 104:21-29.
52. Shah AS, Lilly RE, Kypson AP, et al.: Intracoronary adenovirus-mediated delivery and overexpression of the beta (2)-adrenergic receptor in the heart: prospects for molecular ventricular assistance. Circulation 2000, 101:408-414.
53. Koch WJ, Rockman HA, Samama P, et al.: Cardiac function in mice overexpressing the beta-adrenergic receptor kinase or a beta ARK inhibitor. Science 1995, 268:1350-1353.
54. Rockman HA, Chien KR, Choi DJ, et al.: Expression of a beta-adrenergic receptor kinase 1 inhibitor prevents the development of myocardial failure in gene-targeted mice. Proc Natl Acad Sci U S A 1998, 95:7000-7005.
55. Akhter SA, Skaer CA, Kypson AP, et al.: Restoration of beta-adrenergic signaling in failing cardiac ventricular myocytes via adenoviral-mediated gene transfer. Proc Natl Acad Sci U S A 1997, 94:12100-12105.
56. White DC, Hata JA, Shah AS, et al.: Preservation of myocardial beta-adrenergic receptor signaling delays the development of heart failure after myocardial infarction. Proc Natl Acad Sci U S A 2000, 97:5428-5433.
57. Shah AS, White DC, Emani S, et al.: In vivo ventricular gene delivery of a beta-adrenergic receptor kinase inhibitor to the failing heart reverses cardiac dysfunction. Circulation 2001, 103:1311-1316.
58. Naga Prasad SV, Esposito G, Mao L, et al.: Gβγ-dependent phosphoinositide 3-kinase activation in hearts with in vivo pressure overload hypertrophy. J Biol Chem 2000, 275:4693-4698.
59. Weig HJ, Laugwitz KL, Moretti A, et al.: Enhanced cardiac contractility after gene transfer of V2 vasopressin receptors in vivo by ultrasound-guided injection or transcoronary delivery. Circulation 2000, 101:1578-1585.
60. Roth DM, Gao MH, Lai NC, et al.: Cardiac-directed adenylyl cyclase expression improves heart function in murine cardiomyopathy. Circulation 1999, 99:3099-3102.
61. Sharov VG, Sabbah HN, Shimoyama H, et al.: Evidence of cardiocyte apoptosis in myocardium of dogs with chronic heart failure. Am J Pathol 1996, 148:141-149.
62. Misao J, Hayakawa Y, Ohno M, et al.: Expression of bcl-2 protein, an inhibitor of apoptosis, and Bax, an accelerator of apoptosis, in ventricular myocytes of human hearts with myocardial infarction. Circulation 1996, 94:1506-1512.
63. Wencker D, Chandra M, Armstrong R, et al.: Rescue of dialted cardiomyopathy by caspase inhibition in FKBP-caspase-8 transgenic mice. Circulation 1999, 102:II-28.
64. Haunstetter A, Izumo S: Apoptosis: basic mechanisms and implications for cardiovascular disease. Circ Res 1998, 82:1111-1129.
65. Kirshenbaum LA, de Moissac D: The bcl-2 gene product prevents programmed cell death of ventricular myocytes. Circulation 1997, 96:1580-1585.
66. Brocheriou V, Hagege AA, Oubenaissa A, et al.: Cardiac functional improvement by a human Bcl-2 transgene in a mouse model of ischemia/reperfusion injury. J Gene Med 2000, 2:326-333.
67. Matsui T, Li L, del Monte F, et al.: Adenoviral gene transfer of activated phosphatidylinositol 3′-kinase and Akt inhibits apoptosis of hypoxic cardiomyocytes in vitro. Circulation 1999, 100:2373-2379.
68. Fujio Y, Nguyen T, Wencker D, et al.: Akt promotes survival of cardiomyocytes in vitro and protects against ischemia-reperfusion injury in mouse heart. Circulation 2000, 101:660-667.
69. Cigola E, Kajstura J, Li B, et al.: Angiotensin II activates programmed myocyte cell death in vitro. Exp Cell Res 1997, 231:363-371.
70. Dimmeler S, Rippmann V, Weiland U, et al.: Angiotensin II induces apoptosis of human endothelial cells. Protective effect of nitric oxide. Circ Res 1997, 81:970-976.
71. Leri A, Claudio PP, Li Q, el al.: Stretch-mediated release of angiotensin II induces myocyte apoptosis by activating p53 that enhances the local renin-angiotensin system and decreases the Bcl-2-to-Bax protein ratio in the cell. J Clin Invest 1998, 101:1326-1342.
72. McDonald KM, Mock J, D'Aloia A, et al.: Bradykinin antagonism inhibits the antigrowth effect of converting enzyme inhibition in the dog myocardium after discrete transmural myocardial necrosis. Circulation 1995, 91:2043-2048.
73. Wollert KC, Studer R, Doerfer K, et al.: Differential effects of kinins on cardiomyocyte hypertrophy and interstitial collagen matrix in the surviving myocardium after myocardial infarction in the rat. Circulation 1997, 95:1910-1917.
74. Liu YH, Yang XP, Sharov VG, et al.: Effects of angiotensin-converting enzyme inhibitors and angiotensin II type 1 receptor antagonists in rats with heart failure. Role of kinins and angiotensin II type 2 receptors. J Clin Invest 1997, 99:1926-1935.
75. Yoshida H, Zhang JJ, Chao L, Chao J: Kallikrein gene delivery attenuates myocardial infarction and apoptosis after myocardial ischemia and reperfusion. Hypertension 2000, 35(1 Pt 1):25-31.
76. Agata J, Chao L, Chao J: Kallikrein gene delivery improves cardiac reserve and attenuates remodeling after myocardial infarction. Hypertension 2002, 40:653-659.
77. Cemazar M, Sersa G, Wilson J, et al.: Effective gene transfer to solid tumors using different nonviral gene delivery techniques: electroporation, liposomes, and integrin-targeted vector. Cancer Gene Ther 2002, 9:399-406.
78. Gao GP, Wilson JM, Wivel NA: Production of recombinant adeno-associated virus. Adv Virus Res 2000, 55:529-543.
79. Isner JM: Myocardial gene therapy. Nature 2002, 415:234-239.
80. Hajjar RJ, del Monte F, Matsui T, Rosenzweig A: Prospects for gene therapy for heart failure. Circ Res 2000, 86:616-621.
81. Lynch CM, Hara PS, Leonard JC, et al.: Adeno-associated virus vectors for vascular gene delivery. Circ Res 1997, 80:497-505.
82. Schnepp B, Clark KR: Highly purified recombinant adeno-associated virus vectors. Preparation and quantitation. Methods Mol Med 2002, 69:427-443.
83. Goins WF, Krisky DM, Wolfe DP, et al.: Development of replication-defective herpes simplex virus vectors. Methods Mol Med 2002, 69:481-507.
84. Boeckstegers P, von Degenfeld G, Heinrich D, et al.: Regional myocardial gene transfer using high efficency with selective pressure-regulated retroinfusion of coronary veins. Circulation 1999, 100(suppl I):I-815.